Document is current

Any future updates will be listed below

Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Crossref DOI link: https://doi.org/10.1038/s41467-025-67648-x

Published Online: 2025-12-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark